Exclusive: Price of importing drugs for a Paris and Birmingham study has almost quadrupled to £175,000
British clinical trials of revolutionary cancer treatments are being derailed by red tape and extra costs caused by Brexit, according to a report obtained by the Guardian.
These two examples illustrate how the UK’s departure from the EU is harming UK cancer research, leaving patients in limbo and unable to access pioneering treatments.
Continue reading...